Online citations, reference lists, and bibliographies.

Effect Of Omeprazole, An Inhibitor Of H+, K+-ATPase, On Bone Resorption In Humans

K. Mizunashi, Y. Furukawa, K. Katano, K. Abe
Published 2005 · Medicine, Chemistry
Cite This
Download PDF
Analyze on Scholarcy
Share
SummaryOmeprazole is an inhibitor of gastric H+, K+-ATPase. Although the major proton transport of osteoclast is mediated by a vacuolar-type H+-ATPase which is different from the gastric H+, K+-ATPase,in vitro studies have demonstrated that omeprazole inhibits bone resorption. In this study, the effect of omeprazole on bone resorption was evaluated in patients who had a history of gastric ulcer and were treated with maintenance doses of H2 blocker without any gastric complaints at the study time. H2 blocker administration was changed to omeprazole treatment in the study group and to no treatment in the control group. Urinary excretion of hydroxyproline and calcium decreased after omeprazole treatment in the study group. Serum intact PTH, alkaline phosphatase, osteocalcin, and tartrate-resistant acid phosphatase (TRAP) increased in this group. In the control group, there were not any changes in these parameters. The discrepancy between serum TRAP and urinary excretion of hydroxyproline and calcium in the study group was thought to be due to the suppression of bone resorption by omeprazole, which probably interfered the acidification at resorption lacunae and resulted in the inactivation of TRAP and other lysosomal enzymes. The results of our study suggest the possibility that the specific inhibitors of the osteoclastic proton pump (such as bafilomycins) will more effectively suppress bone resorption and be useful for the treatment of metabolic bone diseases with increased bone resorption.
This paper references
10.1002/jcp.1041320112
Hormonal regulation of acid phosphatase release by osteoclasts disaggregated from neonatal rat bone.
Timothy J. Chambers (1987)
10.1016/0005-2736(91)90238-4
Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases.
J. P. Mattsson (1991)
10.1002/med.2610100102
Omeprazole: the first proton pump inhibitor.
P. Lindberg (1990)
10.1016/0014-4827(88)90191-7
Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts.
I. Silver (1988)
Omeprazole. A survey of preclinical data.
(1985)
10.1016/0006-291X(90)92089-I
Binding site of omeprazole in hog gastric H+,K(+)-ATPase.
Magotoshi Morii (1990)
10.1210/jcem.75.1.1619003
Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia.
Leigh Quarles (1992)
10.1002/ar.1092240220
Molecular mechanisms of bone resorption by the osteoclast.
Roland Baron (1989)
10.1159/000469401
Tartrate-resistant acid phosphatase of human lung: apparent identity with osteoclastic acid phosphatase.
T. Efstratiadis (1985)
10.1016/0009-8981(70)90355-4
The determination of hydroxyproline in urine hydrolysates.
Imanuel. Bergman (1970)
10.1210/jcem-48-4-618
Beta-adrenergically stimulated adenosine 3',5'-monophosphate accumulation in and parathyroid hormone release from dispersed human parathyroid cells.
Edward Meigs Brown (1979)
Protons and osteoclasts.
Timothy R. Arnett (1990)
Parathyroid hormone secretion in primary hyperparathyroidism.
Roger Bouillon (1977)
10.1097/00000441-199202000-00016
The osteoclast as a unicellular proton-transporting epithelium.
S. Gluck (1992)
10.1002/JBMR.5650050606
Biochemical characterization of an electrogenic vacuolar proton pump in purified chicken osteoclast plasma membrane vesicles.
P. J. Bekker (1990)
10.1007/BF02555214
Humoral and ionic regulation of osteoclast acidity
R. E. Anderson (2007)
Development of a high sensitive two site immunoradiometric assay for parathyroid hormone and its clinically utility in evaluation of patients with hypercalcemia
S Nussbaum (1987)
10.1126/science.2528207
Osteoclastic bone resorption by a polarized vacuolar proton pump.
H. Blair (1989)
10.1073/pnas.85.21.7972
Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells.
Emma Jean Bowman (1988)
10.1083/jcb.111.3.1305
Evidence for the presence of a proton pump of the vacuolar H(+)-ATPase type in the ruffled borders of osteoclasts
H. Väänänen (1990)
10.1210/endo-103-6-1969
Comparison of the effects of stimulators and inhibitors of resorption on the release of lysosomal enzymes and radioactive calcium from fetal bone in organ culture.
Gabriel Eilon (1978)
10.1021/jm00158a001
The mechanism of action of the gastric acid secretion inhibitor omeprazole.
P. Lindberg (1986)
10.1083/jcb.101.6.2210
Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border
R. Baron (1985)
10.1007/BF02557836
The rapid appearance of acid phosphatase activity at the developing ruffled border of parathyroid hormone activated medullary bone osteoclasts
Scott Carson Wilmington Miller (2007)
10.1210/edrv-1-4-319
Biogenic amines and the secretion of parathyroid hormone and calcitonin.
Hunter Heath (1980)
10.1002/JBMR.5650040315
Ultrastructural localization of tartrate-resistant, purple acid phosphatase in rat osteoclasts by histochemistry and immunocytochemistry.
S. A. Clark (1989)
10.1016/8756-3282(85)90248-0
Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits prostaglandin stimulated bone resorption in vitro
Juha Tuukkanen (1985)



This paper is referenced by
10.1038/ajg.2016.481
Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure
L. Targownik (2017)
10.1111/jgs.14121
Can We Equate All Proton Pump Inhibitors with One Another?
Fatih Sumer (2016)
10.2165/11536780-000000000-00000
Proton Pump Inhibitors and Fracture Risk
Michael Bodmer (2010)
Impact of omeprazole on bone remodeling in normal and ovariectomized Wistar rats.
Amany H Hasanin (2014)
10.1016/j.amjmed.2009.04.014
Long-term safety concerns with proton pump inhibitors.
Tauseef Ali (2009)
10.1007/s00223-008-9188-4
Increase in Vertebral Fracture Risk in Postmenopausal Women Using Omeprazole
C. Roux (2008)
10.1016/j.maturitas.2009.07.006
Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures.
Marc R Fournier (2009)
10.1517/14740338.2011.586628
The relationship among proton pump inhibitors, bone disease and fracture
Laura E Targownik (2011)
10.1016/J.RBO.2014.05.012
Efeitos da administração em longo prazo do omeprazol sobre a densidade mineral óssea e as propriedades mecânicas do osso
Gabriela Rezende Yanagihara (2015)
10.1016/j.gastrohep.2011.01.002
[Chronic use of proton pump inhibitors: is the risk of osteoporosis and fractures real?].
Miguel Martí-Cabrera (2011)
CHARACTERIZATION OF THE EFFECTS OF PROTON PUMP INHIBITORS ON BONE METABOLISM : IN VITRO STUDY IN CO-CULTURES OF OSTEOCLASTS AND BREAST CANCER CELLS AND IN CULTURES OF OSTEOBLASTS
Sara Daniela de Sousa Reis (2013)
Effects of duration of proton pump inhibitor (PPI) therapy on markers of bone health in men and post-menopausal women
Zarina Pabin (2010)
10.1016/S1734-1140(12)70858-7
Proton pump (H+/K+-ATPase) inhibitors weaken the protective effect of alendronate on bone mechanical properties in estrogen-deficient rats.
Maria Pytlik (2012)
10.1002/9781118444788.CH5
Gastroesophageal Reflux Disease Treatment
David A. Johnson (2013)
Progress in the functions of V-ATPases and its inhibitors
Qin Wen-xin (2009)
10.1016/j.drudis.2009.03.014
Proton pump inhibitors: actions and reactions.
James M Mullin (2009)
10.1007/s11894-010-0141-0
Association of Long-Term Proton Pump Inhibitor Therapy with Bone Fractures and Effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium
T. Ito (2010)
10.1016/j.cgh.2012.11.031
Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence.
David Alan Johnson (2013)
10.1016/j.ijporl.2015.11.023
Stridor and apnea as the initial presentation of primary hypoparathyroidism.
Courtney Chou (2016)
10.1007/s00198-018-4788-y
Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies
Tahmina Nasrin Poly (2018)
10.1053/j.gastro.2010.03.055
Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.
Douglas A. Corley (2010)
PRELIMINARY STUDY IN VIVO OF THE BONE REGENERATIVE CAPACITY OF HYDROXYAPATITE WHEN ASSOCIATED WITH OMEPRAZOLE IN CRITICAL SIZE DEFECTS
Mariana do Souto Fontes Antunes Lopes (2012)
10.1097/MJT.0000000000000154
Hypomagnesemia Among Outpatient Long-Term Proton Pump Inhibitor Users
Murat Bıyık (2017)
10.1007/s00223-018-0432-2
Proton Pump Inhibitor Use, H2-Receptor Antagonist Use, and Risk of Incident Clinical Vertebral Fracture in Women
Julie M Paik (2018)
10.1016/J.JEVS.2015.07.003
Short-Term Omeprazole Use Does Not Affect Serum Calcium Concentrations and Bone Density in Horses
S S Caston (2015)
10.1111/apt.13619
Inulin significantly improves serum magnesium levels in proton pump inhibitor-induced hypomagnesaemia.
M. W. Hess (2016)
10.1007/s00198-017-3910-x
Use of proton pump inhibitors and mortality after hip fracture in a nationwide study
W. Brozek (2017)
10.1111/apt.14345
Incidence and predictors of osteoporotic fractures in patients with Barrett's oesophagus: a population‐based nested case‐control study
S Kumar (2017)
10.1136/ebmed-2012-100650
The association between proton pump inhibitor use and hip fracture cannot be explained by differences in dietary and lifestyle choices
Laura E Targownik (2012)
10.3748/wjg.v23.i14.2575
Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancer
Jin-liang Zhang (2017)
10.1016/J.GASTROHEP.2011.01.002
Es real el riesgo de osteoporosis y riesgo de fracturas con el uso crónico de inhibidores de la bomba de protones
Miguel Martí-Cabrera (2011)
10.5662/wjm.v1.i1.15
Risk of fracture and pneumonia from acid suppressive drugs.
Chun-Sick Eom (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar